Study Protocol: The Efficacy of Mushroom to Reduce Cognitive Decline in At-Risk Middle-aged Adults and Young-olds Living in the Community

Sponsor
National University of Singapore
Study ID
NCT07775833
Status
Recruiting
Apply to this trial

Conditions

  • Cognitive Assessment
  • Dementia

Eligibility Criteria

Sex
ALL
Age
45 Years - 80 Years
Healthy Volunteers
Accepted

Interventions

  • Golden oyster mushroom powder — DIETARY_SUPPLEMENT
    Participants in the intervention group will consume Pleurotus citrinopileatus mushroom powder daily for 24months, with compliance monitored using electronic diary apps. The powder contains 7.0 mg/g of ergothioneine (dry weight).

Study Details

The investigator's objective is to explore the definitive evidence of mushroom on cognitive functions among at-risk middle-aged and young-olds. The investigator carefully designed a randomized controlled trial (RCT) to assess the role of mushrooms in promoting cognitive functioning among around 600 middle-aged adults and young-olds. Participants were selected based on specific inclusion criteria, such as being community-living adults aged 45-80 years with a family history of dementia or subjective cognitive decline, while consuming mushrooms no more than once a week and having no dementia, along with the exclusion of individuals with neurological or psychiatric disorders and significant sensory or motor impairments. Participants in the intervention group will consume Pleurotus citrinopileatus mushroom powder daily for 24months, with compliance

Key Dates

First listed
Aug 20, 2026
Start date
Oct 31, 2026
Status verified
Apr 2026
Primary completion
Dec 31, 2028
Completion
Dec 31, 2030

Study Design

Enrollment
600 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION

Arms

  • Experimental: mushroom powder intervention arm
  • No Intervention: Placebo arm

Primary Outcome Measure

MMSE [ Time Frame: 24 months ]

Central Contacts

Related Studies